Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25072575 | 0.92 | MAPT (0.52) | MAPTESR2NR1H2KCNH2LMNA | |
| SCHEMBL30278525 | 0.92 | MAPT (0.52) | MAPTESR2NR1H2KCNH2LMNA | |
| SCHEMBL4524243 | 0.85 | ESR2 (0.49) | MAPTESR2NR1H2KCNH2LMNA | |
| SCHEMBL19147509 | 0.82 | MAPT (0.45) | MAPTESR2NR1H2KCNH2HTT | |
| SCHEMBL4209617 | 0.81 | MAPT (0.44) | MAPTESR2NR1H2KCNH2LMNA | |
| SCHEMBL30912211 | 0.80 | UCHL1 (0.39) | MAPTESR2KCNH2ROCK2HTT | |
| SCHEMBL30912215 | 0.80 | UCHL1 (0.39) | MAPTESR2KCNH2ROCK2HTT | |
| SCHEMBL30912221 | 0.80 | UCHL1 (0.39) | MAPTESR2KCNH2ROCK2HTT | |
| SCHEMBL13568090 | 0.79 | MAPT (0.41) | MAPTESR2NR1H2KCNH2LMNA | |
| SCHEMBL4203005 | 0.79 | USP2 (0.47) | MAPTESR2NR1H2GPR119USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| EP-2094695-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | Cascade Therapeutics Inc. (CA) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | MAPT 2939/4885ESR2 550/4885NR1H2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.